• Corporate Overview
• Leadership
• > Management
• > Board of Directors
• > Scientific Founders
• > Scientific Advisors
• Collaborations
• Contact Us

Leadership - Management

Mark J. Enyedy
Chief Executive Officer

Mr. Enyedy joined Proteostasis in September 2011 after serving 15 years with Genzyme Corporation, most recently as President of the Transplant/Oncology and Multiple Sclerosis divisions. As a member of Genzyme’s senior management team, he provided operational oversight and global P&L management, strategic and portfolio planning, and leadership development for both divisions. These activities included the build-out of a commercial oncology franchise and the integration of the Transplant and Oncology divisions, creating a seven-product portfolio focused on the hematology/oncology and transplant markets with over $675 million in revenue. Additionally, he oversaw the pivotal development of alemtuzumab in Multiple Sclerosis, Genzyme’s largest R&D program to date, directed two global product launches, led multiple M&A transactions, and chaired the Genzyme Portfolio Management Committee. Prior to joining general management, Mr. Enyedy served as Vice President, Business Development and Director, Business Development for the Oncology division where he completed a significant number of licensing and partnering transactions. Before joining Genzyme, Mr. Enyedy served as an associate in the business law department at Palmer & Dodge. Mr. Enyedy received his J.D. from Harvard Law School and his B.S. from Northeastern University.

• Peter H. Reinhart, Ph.D.
  President and Chief Scientific Officer

  Dr. Reinhart joined Proteostasis in February 2010. He previously oversaw Neurodegeneration Research at Wyeth Pharmaceuticals and Pfizer, focusing on Alzheimer's disease, Parkinson’s disease, stroke regeneration, and ALS programs. During his six-year tenure there, Dr. Reinhart delivered numerous small molecule as well as biomolecule drug candidates into clinical development. Prior to joining Wyeth, he served as Vice President, Neurodegeneration at Cogent Neuroscience after twelve years as a faculty member at Duke University Medical Center, where he continues to serve as an adjunct professor. Dr. Reinhart is on the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, and contributes to numerous government and foundation grant review boards. Dr. Reinhart received a B.Sc. and Ph.D. in Biochemistry from the Australian National University and did his postdoctoral training in Neurobiology at the University of Tuebingen, Germany, and was a research fellow at Brandeis University. He has authored more than 90 publications, and serves as a scientific reviewer for Science, Neuron, Nature Drug Discovery, Journal of Neuroscience, and Molecular Pharmacology.

• Dan Garza, Ph.D.
  Head of Cellular & Molecular Biology

  Prior to joining Proteostasis in November 2008, Dr. Garza was an Executive Director in the Department of Functional Genomics and led a Stress Response Pathways Program at the Novartis Institutes for Biomedical Research. Prior to joining Novartis, from 1994 to 2001, he was an Assistant Professor in the Program in Medical Sciences at Florida State University, where he studied genome structure and function as well as steroid hormone signaling in Drosophila. He is an author on over 30 scientific publications. He received his B.S. in Biochemistry from SUNY Stonybrook, his Ph.D. in Molecular Biology from Washington University School of Medicine, St. Louis and was a Helen Hay Whitney post-doctoral fellow in the Department of Developmental Biology at Stanford University Medical School.

• Hui Ge, Ph.D.
  Head of Systems Biology

  Dr. Ge joined Proteostasis in December 2008.  Previously, she led a computational biology lab at the Whitehead Institute for Biomedical Research.  Dr. Ge pioneered system-level studies of protein networks and developed predictive models of gene function in organism development and diseases.  Her achievements include devising a variety of novel computational approaches for integrating various types of high-throughput biological data.  Her research has been published in top scientific journals including Nature, Science, and Cell.  She received a B.S. from Beijing University and a Ph.D. from Harvard University.

• Brad Geddes, Ph.D.
  Head of Pharmacology

  Prior to joining Proteostasis in March of 2009, Dr. Geddes was Senior Director of Drug Discovery at Elixir Pharmaceuticals, Inc. where he was responsible for preclinical development programs focused on metabolic disease, including their ghrelin receptor antagonist program recently partnered with Novartis.  Previously, at MDS Proteomics, he was project manager for a $45M collaboration with Cephalon Inc.  From 1999 to 2003, Dr. Geddes worked at Millennium Pharmaceuticals, Inc. in the areas of neurodegenerative and metabolic diseases. He is an author on over 25 scientific articles and book chapters.  He received both his BSc in Biology and MSc in Neuroendocrinology from the University of Guelph (Canada) and received his Ph.D. in Molecular Neurobiology from the University of Bristol, UK.

  
  

• J. Steven Jacobsen, Ph.D.
  Head of Translational Biology
  
• Dr. Jacobsen joined Proteostasis in May 2010 after a 22-year career at Pfizer and predecessor companies Wyeth and Lederle. He headed the Alzheimer’s research efforts for 15 years, during which he delivered eight small molecules, vaccines and biologics into development. Dr. Jacobsen is recognized as a pharmaceutical expert in Alzheimer’s disease and is frequently invited to speak at international academic conferences on various discovery, biomarker/translation, and early clinical development programs and has also represented PhRMA (the industry trade group, Pharmaceutical Research and Manufacturers of America) in various meetings on Capitol Hill. He is an author on over 50 publications, serves as an Associate Editor for Current Alzheimer Research, and is an Adjunct Associate Professor at Ohio State University and at the New York University School of Medicine. Dr Jacobsen received his B.S. in Biology and M.S. in Microbiology from Seton Hall University and his Ph.D. in Molecular Genetics and Microbiology from the New Jersey Medical School at the University of Medicine and Dentistry of New Jersey.
• Walter Newman, Ph.D.
  Head of External Innovation
  
• Dr. Newman, in his role at HealthCare Ventures, worked closely with the scientific founders to facilitate the start of Proteostasis Therapeutics, Inc. in early 2007. Dr. Newman has been a Director at HealthCare Ventures since 2006, and, prior to that, has held a series of senior level positions in Cambridge startups, including as the Senior Vice President of R&D and Chief Scientific Officer at Critical Therapeutics and SVP for Research at LeukoSite (and subsequently SVP of Biotherapeutics at Millenium Pharmaceuticals after LeukoSite was acquired by Millennium). Prior to that, Dr Newman had group leadership responsibilities for anti-inflammatory drug discovery at Otsuka Pharmaceuticals and Ortho Pharmaceuticals. Prior to an academic career at the Fred Hutchinson Cancer Research Center in Seattle, Dr. Newman did his doctoral and postdoctoral training in immunology at Columbia University and the Albert Einstein College of Medicine, respectively. He has authored over 80 peer reviewed papers and holds numerous patents.
  
  

• Bradley Tait, Ph.D.
  Head of Chemistry

  Dr. Tait joined Proteostasis in November 2008.  He has over 20 years of experience in the pharmaceutical industry at Schering Plough, Parke-Davis and Pfizer, including eight years of drug discovery management. His experience spans multiple therapeutic areas, including infectious disease, CNS, allergy/respiratory, inflammation and cardiovascular. He has delivered seventeen compounds into clinical development and contributed to 20 patents and 25 publications. Dr. Tait received a Ph.D. from Wayne State University and did post-doctoral work at Yale University.